Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
References (51)
Epidemiology of coronary heart disease: The Framingham Study
Am J Med
(1984)Management of hypercholesterolemia
Med Clin North Am
(2000)Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
Life Sci
(1999)- et al.
Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner
J Nutr
(2000) - et al.
The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically
Atherosclerosis
(2000) - et al.
The cholesterol inhibitor ezetimibe inhibits the development of atherosclerosis in apo E knockout (-/-) mice fed low fat and Western diets
Atherosclerosis
(2000) - et al.
The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys
Eur J Pharmacol
(2001) - et al.
Effect of ezetimibe on serum concentrations of lipid-soluble vitamins
Atherosclerosis
(2001) - et al.
Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe
Atherosclerosis
(2001) - et al.
Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications
Atherosclerosis
(2001)
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin
Atherosclerosis
(2000)
(1994)
(2000)
Serum cholesterol, lipoproteins, and the risk of coronary heart disease
Ann Intern Med
(1971)
Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the Seven Countries Study
JAMA
(1995)
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
JAMA
(1986)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
N Engl J Med
(1995)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
JAMA
(1998)
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
Lancet
(1995)
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
Circulation
(1998)
Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
N Engl J Med
(1998)
Lipoprotein metabolism
Eur Heart J
(1998)
Cholesterol biosynthesis and metabolism
Cardiovasc Drugs Ther
(1992)
Drugs used in the treatment of hyperdyslipidemias
Lipid-altering drugs in development
Drugs R D
(1999)
Cited by (309)
Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics
2023, Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic MedicineTailor-made amino acids in the design of small-molecule blockbuster drugs
2021, European Journal of Medicinal ChemistryLipid management to reduce cardiovascular risk in type 2 diabetes
2023, Diabetologie
- 1
Members of the Ezetimibe Study Group are listed in the Acknowledgments.
Copyright © 2001 Published by Elsevier Inc.